Balchem Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Balchem heeft de winst zien groeien met een gemiddeld jaarlijks percentage van 11.7%, terwijl de Chemicals-industrie de winst zag dalen met 2.9% per jaar. De inkomsten zijn gegroeid met een gemiddeld jaarlijks percentage van 5.6%. Het rendement op eigen vermogen van Balchem is 12.6%, en het heeft een nettomarge van 15.1%.
Belangrijke informatie
11.68%
Groei van de winst
11.61%
Groei van de winst per aandeel
| Chemicals Groei van de industrie | 12.93% |
| Inkomstengroei | 5.60% |
| Rendement op eigen vermogen | 12.62% |
| Nettomarge | 15.14% |
| Laatste winstupdate | 30 Jun 2026 |
Recente prestatie-updates uit het verleden
Recent updates
Narratiefupdate • Aug 18
BCPC: Share Buybacks And Index Additions Will Support Future Upside Potential
Analysts have raised their fair value estimate for Balchem from $234 to $242, linking the change to updated assumptions for revenue growth, profit margin, and future P/E that are now reflected in the latest price target reset. What’s in the News for Balchem From April 1, 2026 to June 30, 2026, Balchem repurchased 183,249 shares for US$29.64 million, representing 0.57% of shares under its ongoing buyback program.
Narratiefupdate • Aug 04
BCPC: Record Earnings And Buybacks Will Support Strong Future Returns
Analysts have raised their price target for Balchem to $207.00 from $200.75, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What’s in the News for Balchem Balchem reported record Q2 2026 net sales, net earnings, and adjusted EBITDA, with revenue at US$284.0 million.Seeking Alpha • Aug 02
Balchem: It's A Buy From Me After Posting Strong Q2 Results
Summary Balchem Corporation posted Q2 results, with EPS of $1.49 beating estimates by $0.07, while surpassing the consensus by $15M and was up 11% YoY. All areas of the business posted impressive results, as the minimum revenue growth for a segment was 8.9%, while the peak was 15% in Animal Nutrition & Health. The stock appears to be trading for a ~9% discount to its fair value right now based on my FCF valuation model. Read the full article on Seeking AlphaNarratiefupdate • Jun 26
BCPC: Share Repurchases And Strong Margins Will Support Future Returns
Analysts have lifted their Balchem fair value estimate from $191 to about $200.75, citing updates to their models that include revised assumptions for revenue growth, profit margins, the discount rate, and Balchem's future P/E multiple. What’s in the News for Balchem Balchem reported that from January 1, 2026 to March 31, 2026, the company repurchased 89,880 shares, representing 0.28% of its shares, for US$14.92 million under its existing buyback program.Nieuw narratief • Mar 13
Long-Term Nutrition And Health Trends Will Support Stronger Margins And Earnings Potential
Catalysts About Balchem Balchem supplies specialty nutrients and ingredients for human, animal and plant health, along with performance gases and related solutions. What are the underlying business or industry changes driving this perspective?
Nieuw narratief • Feb 26
Encapsulation Investments And International Expansion Will Shape Balanced Future For Nutrition Specialist
Catalysts About Balchem Balchem produces specialty nutrition and ingredient solutions for human, animal and plant health, along with performance gases. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Feb 17
BCPC: Dividend Increase And Buyback Program Will Support Steady Future Returns
Analysts kept their Balchem fair value estimate broadly steady at $191, pointing to only very small tweaks in assumptions such as discount rate, long term revenue growth, profit margin and future P/E as the basis for maintaining their target level. What's in the News On December 9, 2025, Balchem Corporation's Board of Directors declared an annual dividend of $0.96 per share, payable on January 20, 2026, to stockholders of record as of December 23, 2025.Analyse-artikel • Feb 15
If EPS Growth Is Important To You, Balchem (NASDAQ:BCPC) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Narratiefupdate • Feb 03
BCPC: Share Repurchases And Higher Dividend Will Support Attractive Future Returns
Analysts have maintained their fair value estimate for Balchem at US$191. They have made only minimal adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions, indicating that their overall view on the stock's valuation drivers remains essentially unchanged.Analyse-artikel • Feb 01
Is Now An Opportune Moment To Examine Balchem Corporation (NASDAQ:BCPC)?
Balchem Corporation ( NASDAQ:BCPC ), is not the largest company out there, but it saw a decent share price growth of...Narratiefupdate • Jan 20
BCPC: Share Repurchases And Rising Dividend Will Support Attractive Future Returns
Analysts have maintained their Balchem fair value estimate at US$191, with only small tweaks to the discount rate, revenue growth, profit margin, and forward P/E assumptions. This reflects a largely unchanged view on the stock's risk and earnings profile.Narratiefupdate • Jan 05
BCPC: Share Repurchases And Dividend Increases Will Support Attractive Future Returns
Analysts kept their fair value estimate for Balchem steady at US$191, pointing to only very small model tweaks in the discount rate, revenue growth, margin and forward P/E assumptions rather than any change in their overall view of the company. What's in the News Balchem Corporation announced a share repurchase program authorizing the company to buy back up to 4,000,000 shares, with no expiration date on the program (Key Developments).Narratiefupdate • Dec 20
BCPC: Share Repurchases And Dividend Increases Will Drive Attractive Future Returns
Analysts have maintained their price target on Balchem at approximately $191.00. This reflects only marginal tweaks to underlying assumptions such as discount rate, revenue growth, and profit margin, rather than a material change in their outlook.Narratiefupdate • Dec 06
BCPC: Share Repurchases Will Support Attractive Long Term Return Potential
Analysts have lowered their price target on Balchem by approximately $9 to about $191 per share, reflecting more cautious assumptions around revenue growth and profit margins, even though long term valuation multiples are slightly higher. What's in the News Completed a long running share repurchase program, buying back a total of 3,475,622 shares, or about 12.76% of shares outstanding, for approximately $190.58 million since the authorization began in 1999 (Key Developments) During the most recent quarter from July 1, 2025 to September 30, 2025, repurchased 95,760 shares, roughly 0.3% of shares outstanding, for $15.42 million as the final tranche under the existing buyback plan (Key Developments) Valuation Changes The Fair Value Estimate has fallen modestly from about $200.33 to $191.00 per share, reflecting a slightly more conservative outlook.Analyse-artikel • Dec 01
Balchem (NASDAQ:BCPC) Is Experiencing Growth In Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Analyse-artikel • Oct 10
Some Shareholders Feeling Restless Over Balchem Corporation's (NASDAQ:BCPC) P/E Ratio
Balchem Corporation's ( NASDAQ:BCPC ) price-to-earnings (or "P/E") ratio of 31.9x might make it look like a strong sell...Analyse-artikel • Sep 26
Balchem (NASDAQ:BCPC) Could Easily Take On More Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Oct 28
Balchem's Q3 Shows Record Earnings And Valuation Pressure
Summary Balchem Corporation shows strong long-term growth potential in high-margin segments and product innovation, but faces challenges in Animal Nutrition & Health and rising costs. Balchem's financial momentum in Q3 2024 includes record earnings, improved margins, and significant debt reduction, despite missing revenue estimates. BCPC stock's high P/E ratio of 39.82x suggests big market expectations, but the current valuation may be too high given existing challenges. I rate Balchem as a “Hold” due to high valuation, operational challenges, and potential seasonal slowdown, advising cautious investors to wait for a better entry point. Read the full article on Seeking Alpha
Nieuw narratief • Aug 29
Innovating In Nutrition And Health Sectors Drives Strong Financial Growth And Market Expansion
Launch of Optifolin+ in the nutrition segment and strong Human Nutrition & Health sales indicate potential for market share expansion and sustained revenue growth.Seeking Alpha • May 10
Balchem: A Tale Of Two Businesses
Summary Balchem Corporation's Q1 2024 earnings surpassed expectations, but the company's full-year bottom-line expansion could be slower than what it achieved for the first quarter. The Human Nutrition & Health segment is riding on the supplements market's growth, while the Animal Nutrition & Health segment is encountering stiff competition in the European animal feed market. It is a tale of two businesses for BCPC, which implies that the stock warrants a Neutral or Hold rating. Read the full article on Seeking AlphaSeeking Alpha • Feb 21
Balchem: Potential Turnaround Is In The Price
Summary Balchem registered a -2.5% top-line miss for the fourth quarter of 2023, which is attributable to the underperformance of its Animal Nutrition business. BCPC is well-positioned to achieve positive top line and earnings expansion in the current year, but I deem the stock's valuations to be fair. The Company continues to be rated as a Hold, as my opinion is that the expected 2024 turnaround for BCPC is priced in. Read the full article on Seeking AlphaOpbrengsten en kosten
Opbrengsten en kosten
Hoe Balchem geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 26 | 1,086 | 164 | 152 | 20 |
| 31 Mar 26 | 1,057 | 158 | 150 | 20 |
| 31 Dec 25 | 1,037 | 155 | 143 | 19 |
| 30 Sep 25 | 1,014 | 149 | 140 | 18 |
| 30 Jun 25 | 986 | 143 | 137 | 18 |
| 31 Mar 25 | 965 | 137 | 133 | 17 |
| 31 Dec 24 | 954 | 128 | 136 | 17 |
| 30 Sep 24 | 942 | 122 | 144 | 16 |
| 30 Jun 24 | 932 | 117 | 139 | 16 |
| 31 Mar 24 | 930 | 115 | 131 | 16 |
| 31 Dec 23 | 922 | 109 | 120 | 15 |
| 30 Sep 23 | 926 | 103 | 117 | 14 |
| 30 Jun 23 | 941 | 99 | 122 | 13 |
| 31 Mar 23 | 946 | 99 | 126 | 12 |
| 31 Dec 22 | 942 | 105 | 121 | 12 |
| 30 Sep 22 | 923 | 109 | 116 | 14 |
| 30 Jun 22 | 877 | 109 | 109 | 14 |
| 31 Mar 22 | 842 | 102 | 107 | 14 |
| 31 Dec 21 | 799 | 96 | 102 | 14 |
| 30 Sep 21 | 767 | 93 | 100 | 11 |
| 30 Jun 21 | 744 | 90 | 100 | 11 |
| 31 Mar 21 | 715 | 88 | 99 | 10 |
| 31 Dec 20 | 704 | 85 | 102 | 10 |
| 30 Sep 20 | 689 | 83 | 104 | 11 |
| 30 Jun 20 | 673 | 82 | 104 | 11 |
| 31 Mar 20 | 661 | 81 | 102 | 11 |
| 31 Dec 19 | 644 | 80 | 95 | 11 |
| 30 Sep 19 | 641 | 80 | 89 | 12 |
| 30 Jun 19 | 637 | 78 | 84 | 12 |
| 31 Mar 19 | 639 | 78 | 82 | 12 |
| 31 Dec 18 | 644 | 79 | 84 | 12 |
| 30 Sep 18 | 639 | 100 | 83 | 11 |
| 30 Jun 18 | 635 | 97 | 84 | 11 |
| 31 Mar 18 | 618 | 94 | 81 | 10 |
| 31 Dec 17 | 595 | 90 | 81 | 9 |
| 30 Sep 17 | 576 | 64 | 82 | 9 |
| 30 Jun 17 | 564 | 62 | 82 | 8 |
| 31 Mar 17 | 556 | 60 | 82 | 7 |
| 31 Dec 16 | 553 | 56 | 83 | 7 |
| 30 Sep 16 | 545 | 56 | 77 | 7 |
| 30 Jun 16 | 547 | 56 | 76 | 7 |
| 31 Mar 16 | 543 | 56 | 72 | 6 |
| 31 Dec 15 | 552 | 60 | 68 | 6 |
| 30 Sep 15 | 582 | 63 | 71 | 6 |
Kwaliteitswinsten: BCPC heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (15.1%) BCPC } zijn hoger dan vorig jaar (14.5%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van BCPC is de afgelopen 5 jaar met 11.7% per jaar gegroeid.
Versnelling van de groei: De winstgroei van BCPC over het afgelopen jaar ( 15.2% ) overtreft het 5-jarig gemiddelde ( 11.7% per jaar).
Winst versus industrie: De winstgroei BCPC over het afgelopen jaar ( 15.2% ) overtrof de Chemicals -sector 2.4%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 12.6% ) van BCPC wordt als laag beschouwd.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/10 14:57 |
| Aandelenkoers aan het einde van de dag | 2026/09/10 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Balchem Corporation wordt gevolgd door 9 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Robert Labick | CJS Securities, Inc. |
| Timothy Ramey | D.A. Davidson & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |